Amelioration of deficit syndrome of schizophrenia by norepinephrine reuptake inhibitor

Therapeutic Advances in Psychopharmacology

Volumn 5, Issue 5, 2015, Pages 263-270

  Shoja Shafti, Saeed ^a   Jafarabad, Mohammad Sadeghe ^b   Azizi, Reza ^b  

^a UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

^b Razi Psychiatric Center   (Iran)

Author keywords

deficit syndrome; negative symptoms; noradrenalin reuptake inhibitors; reboxetine; schizophrenia

Indexed keywords

HALOPERIDOL; PLACEBO; REBOXETINE;

ADJUVANT THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HAMILTON DEPRESSION RATING SCALE; HEADACHE; HUMAN; INSOMNIA; MALE; MINI-MENTAL STATUS EXAMINATION; NEGATIVE SYNDROME; PARALLEL DESIGN; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RATING SCALE; SCALE FOR ASSESSMENT OF NEGATIVE SYMPTOMS; SCALE FOR ASSESSMENT OF POSITIVE SYMPTOMS; SCHIZOPHRENIA; SIMPSON ANGUS SCALE; XEROSTOMIA;

EID: 84998044288     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125315591953     Document Type: Article

References (25)

1. Andreasen N. (1981) The Scale for Assessment of Negative Symptoms (SANS). Iowa City, IA: Department of Psychiatry, University of Iowa.
2. Andreasen N. (1982) Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 39: 784–788.
3. Andreasen N. (1984) The Scale for Assessment of Positive Symptoms (SAPS). Iowa City, IA: Department of Psychiatry, University of Iowa.
4. Andreasen N. (1989) The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl 7: 49–58.
5. APA (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text revision. Washington, DC: American Psychiatric Association.
6. Baldessarini R. (2010) Drugs and the treatment of psychiatric disorders: depression and anxiety disorders. In: Hardman J. Limbird L. Goodman Gilman A (eds), Goodman & Gilman's Pharmacological Basis of Therapeutics, 10th edn. New York: McGraw-Hill, p. 447.
7. Buchanan R. Carpenter W. (1994) Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis 182: 193–204.
8. Carpenter W. (1997) Pharmacotherapy of schizophrenia: negative symptoms. Am J Psychiatr 154: 123–129.
9. Crow T. (1985) The two-syndrome concept: origins and current status. Schizophr Bull 11: 471–486.
10. Folstein M. Folstien S. McHugh P. (1975) Mini- mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189.
11. Hamilton M. (1960) Rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56.
12. Kay S. Fiszbein A. Opler L. (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261–276.
13. Kishi T. Mukai T. Matsuda Y. Moriwaki M. Iwata N. (2013) Efficacy and safety of noradrenalin reuptake inhibitor augmentation therapy for schizophrenia: a meta-analysis of double-blind randomized placebo-controlled trials. J Psychiatr Res 47: 1557–1563.
14. Kraepelin E. (1971) Dementia Praecox and Paraphrenia [translated by Barclay R.M.]. Huntington, NY: Robert E. Krieger Publishing.
15. Poyurovsky M. Isaacs I. Fuchs C. Schneidman M. Faragian S. Weizman R. et al. (2003) Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatr 160: 297–302.
16. Raedler T. Jahn H. Arlt J. Kiefer F. Schick M. Naber D. et al. (2004) Adjunctive use of reboxetine in schizophrenia. Eur Psychiatry 19: 366–9.
17. Schutz G. Berk M. (2001) Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 16: 275–8.
18. Shoja Shafti S. (2006) Treatment-responsiveness of negative symptoms in schizophrenia: a double-blind placebo-control clinical trial. Iranian J Med Sci 31: 135–138.
19. Shoja Shafti S. (2007) Amelioration of negative symptoms in schizophrenia by escitalopram: a double blind, placebo-controlled clinical trial. Clin Schizophrenia Related Psychosis 1: 255–258.
20. Simpson G. Angus J. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatry Scand 212: 11–9.
21. Strauss G. Gold J. (2012) A new perspective on anhedonia in schizophrenia. Am J Psychiatry 169: 364–373.
22. Strauss J. Carpenter W. Bartko J. (1974) The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull 11: 61–69.
23. Strauss G. Harrow M. Grossman L. Rosen C. (2010) Periods of recovery in deficit syndrome schizophrenia: a 20-year multifollowup longitudinal study. Schizophr Bull 36: 788–799.
24. Taylor D. Paton C. Kapur S. (2012) The Maudsley Prescribing Guidelines in Psychiatry, 11th edn. Oxford, UK: Wiley-Blackwell, pp. 57–59.
25. Weiss J. Dormann S. Facklam M. Kerpen C. Ketabi N. Haefeli W. (2003) Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305: 197–204.